 Justin Honce
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 16 | 2024 | 3408 | 1.100 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 436 | 0.770 |
Why?
| | Immunologic Factors | 2 | 2019 | 231 | 0.650 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 18 | 0.630 |
Why?
| | Psychotherapy | 1 | 2020 | 157 | 0.610 |
Why?
| | Rituximab | 1 | 2019 | 164 | 0.580 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2019 | 73 | 0.570 |
Why?
| | Epilepsy | 2 | 2017 | 329 | 0.470 |
Why?
| | Neuroimaging | 1 | 2016 | 279 | 0.430 |
Why?
| | Meningeal Neoplasms | 3 | 2021 | 93 | 0.360 |
Why?
| | Natalizumab | 2 | 2021 | 40 | 0.330 |
Why?
| | Meningioma | 2 | 2021 | 82 | 0.320 |
Why?
| | Cochlear Implantation | 2 | 2023 | 88 | 0.320 |
Why?
| | Cochlear Implants | 2 | 2023 | 105 | 0.320 |
Why?
| | Brain Concussion | 1 | 2016 | 548 | 0.300 |
Why?
| | Central Nervous System | 2 | 2021 | 257 | 0.290 |
Why?
| | Brain | 5 | 2024 | 2679 | 0.280 |
Why?
| | Pyrazoles | 3 | 2021 | 405 | 0.270 |
Why?
| | Pyrimidines | 2 | 2021 | 459 | 0.260 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 1052 | 0.250 |
Why?
| | Pyridines | 2 | 2021 | 478 | 0.230 |
Why?
| | Atrophy | 2 | 2024 | 171 | 0.230 |
Why?
| | Frontotemporal Dementia | 1 | 2024 | 37 | 0.230 |
Why?
| | Central Nervous System Diseases | 1 | 2023 | 68 | 0.190 |
Why?
| | Middle Aged | 15 | 2024 | 31154 | 0.190 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2344 | 0.190 |
Why?
| | Intracranial Aneurysm | 1 | 2022 | 95 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2021 | 30 | 0.180 |
Why?
| | Hypnosis | 1 | 2020 | 6 | 0.170 |
Why?
| | Relaxation Therapy | 1 | 2020 | 17 | 0.170 |
Why?
| | Parkinson Disease | 2 | 2017 | 463 | 0.170 |
Why?
| | Radiology, Interventional | 1 | 2020 | 30 | 0.170 |
Why?
| | Humans | 26 | 2024 | 129650 | 0.170 |
Why?
| | Software | 1 | 2024 | 608 | 0.160 |
Why?
| | Radiology Department, Hospital | 1 | 2019 | 16 | 0.160 |
Why?
| | Skull Base Neoplasms | 1 | 2019 | 26 | 0.160 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 22 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 2061 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2024 | 519 | 0.150 |
Why?
| | Cerebral Arterial Diseases | 1 | 2019 | 48 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 70 | 0.150 |
Why?
| | Neurologic Examination | 1 | 2019 | 115 | 0.150 |
Why?
| | Lactams, Macrocyclic | 1 | 2018 | 49 | 0.150 |
Why?
| | Blepharospasm | 1 | 2018 | 7 | 0.150 |
Why?
| | Torticollis | 1 | 2018 | 12 | 0.150 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 84 | 0.150 |
Why?
| | Basal Ganglia | 1 | 2018 | 53 | 0.150 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 11 | 0.150 |
Why?
| | Organophosphorus Compounds | 1 | 2018 | 79 | 0.140 |
Why?
| | Fingolimod Hydrochloride | 1 | 2018 | 39 | 0.140 |
Why?
| | Adult | 11 | 2022 | 35576 | 0.140 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2017 | 20 | 0.140 |
Why?
| | Disability Evaluation | 1 | 2019 | 284 | 0.140 |
Why?
| | Brain Neoplasms | 2 | 2016 | 1171 | 0.130 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 33 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 481 | 0.130 |
Why?
| | Spin Labels | 1 | 2016 | 47 | 0.130 |
Why?
| | Cerebellum | 1 | 2018 | 219 | 0.130 |
Why?
| | Surgery, Computer-Assisted | 1 | 2017 | 76 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 77 | 0.120 |
Why?
| | Medical Marijuana | 1 | 2017 | 111 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2019 | 321 | 0.120 |
Why?
| | Laser Therapy | 1 | 2017 | 131 | 0.120 |
Why?
| | Gray Matter | 1 | 2015 | 81 | 0.120 |
Why?
| | Cerebrovascular Circulation | 1 | 2016 | 226 | 0.110 |
Why?
| | Gene Rearrangement | 1 | 2015 | 148 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 173 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2019 | 1876 | 0.110 |
Why?
| | Mitochondrial Diseases | 1 | 2015 | 90 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 853 | 0.110 |
Why?
| | Nucleus Accumbens | 1 | 2015 | 126 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2015 | 231 | 0.100 |
Why?
| | Anxiety | 1 | 2020 | 966 | 0.100 |
Why?
| | Endovascular Procedures | 1 | 2017 | 301 | 0.100 |
Why?
| | Male | 14 | 2024 | 63681 | 0.100 |
Why?
| | Glioma | 1 | 2016 | 354 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2019 | 902 | 0.100 |
Why?
| | Female | 14 | 2024 | 68776 | 0.100 |
Why?
| | Contrast Media | 3 | 2021 | 394 | 0.090 |
Why?
| | Quality Improvement | 1 | 2019 | 1103 | 0.090 |
Why?
| | Brain Injuries | 1 | 2016 | 468 | 0.090 |
Why?
| | Artifacts | 2 | 2023 | 126 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1434 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1071 | 0.090 |
Why?
| | Cannabis | 1 | 2017 | 465 | 0.080 |
Why?
| | Aged | 8 | 2024 | 22103 | 0.080 |
Why?
| | Young Adult | 3 | 2021 | 12426 | 0.080 |
Why?
| | Hippocampus | 1 | 2015 | 874 | 0.080 |
Why?
| | Quality of Life | 1 | 2021 | 2704 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2022 | 14518 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1838 | 0.070 |
Why?
| | Substance-Related Disorders | 1 | 2015 | 1022 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2024 | 7086 | 0.060 |
Why?
| | Adolescent | 2 | 2021 | 20393 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3083 | 0.060 |
Why?
| | Monkeypox virus | 1 | 2023 | 13 | 0.050 |
Why?
| | Angiography, Digital Subtraction | 1 | 2022 | 43 | 0.050 |
Why?
| | Cerebral Angiography | 1 | 2022 | 109 | 0.050 |
Why?
| | Computed Tomography Angiography | 1 | 2022 | 115 | 0.050 |
Why?
| | Dementia | 1 | 2024 | 227 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2023 | 539 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2635 | 0.040 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 2019 | 6 | 0.040 |
Why?
| | Time Management | 1 | 2019 | 19 | 0.040 |
Why?
| | Magnets | 1 | 2019 | 19 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2018 | 10230 | 0.040 |
Why?
| | Transportation of Patients | 1 | 2019 | 50 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2022 | 246 | 0.040 |
Why?
| | Appointments and Schedules | 1 | 2019 | 84 | 0.040 |
Why?
| | Lactams | 1 | 2018 | 21 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3794 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2019 | 133 | 0.040 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2018 | 19 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 88 | 0.040 |
Why?
| | Aminopyridines | 1 | 2018 | 97 | 0.040 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 30 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 76 | 0.040 |
Why?
| | Gadolinium | 1 | 2018 | 78 | 0.040 |
Why?
| | Dura Mater | 1 | 2017 | 30 | 0.030 |
Why?
| | Lymphoma, B-Cell | 1 | 2018 | 105 | 0.030 |
Why?
| | Mood Disorders | 1 | 2017 | 120 | 0.030 |
Why?
| | Radiosurgery | 1 | 2019 | 321 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 610 | 0.030 |
Why?
| | Memory Disorders | 1 | 2017 | 168 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 303 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 769 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 1007 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 467 | 0.030 |
Why?
| | Disabled Persons | 1 | 2017 | 140 | 0.030 |
Why?
| | Memory | 1 | 2017 | 255 | 0.030 |
Why?
| | Fatigue | 1 | 2017 | 318 | 0.030 |
Why?
| | Limbic System | 1 | 2015 | 47 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1274 | 0.030 |
Why?
| | Affect | 1 | 2017 | 286 | 0.030 |
Why?
| | Tremor | 1 | 2015 | 60 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 44 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1206 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1127 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2017 | 247 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1952 | 0.030 |
Why?
| | Internet | 1 | 2017 | 617 | 0.030 |
Why?
| | Anticoagulants | 1 | 2017 | 637 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2535 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2742 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4421 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1968 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4897 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6556 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5406 | 0.010 |
Why?
| | Obesity | 1 | 2017 | 2883 | 0.010 |
Why?
|
|
Honce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|